Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Spirax Group keeps sales guidance, but FX to weigh on profits
(Sharecast News) - Engineering firm Spirax Group has maintained its guidance for organic sales growth this year despite ongoing weakness in the wider market, though foreign exchange headwinds will impact profits more than previously thought. Spirax Group, which rebranded from Spirax-Sarco Engineering earlier this year, said currency headwinds are expected to persist during 2024, with an impact of around 3% to sales and 6% to adjusted operating profit. The sales impact was downgraded from 5% at the time of its full-year results in March.
However, the company is still guiding to mid to high-single-digit organic growth in revenues, and modest progress in the adjusted operating profit margin from 20.7% last year.
Organic sales increased by a low-single-digit percentage during the first four months of the year, in line with the board's expectations, given strong comparatives last year and ongoing weakness in key markets.
According to industry forecasts by CRH Economics, global industrial production grew by just 1.7% in the first quarter, with IP growth negative in the US, Germany and South America, while weakening in China. However, IP is tipped to recover later in the year.
Spirax said demand was broadly flat on last year during the first four months of 2024, with demand from biopharm customers starting to show "early signs of improvement", though there has been no increase in demand from semiconductor wafer fabrication equipment (or semicon) customers.
"We continue to anticipate mid to high-single-digit organic growth in group revenues, in line with the forecast phasing of IP and an increase in Biopharm and Semicon demand during the latter part of the year," the company said in a statement.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.